New obesity drug tested for safety with heart and cholesterol meds
NCT ID NCT07128888
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 27 times
Summary
This early-stage study looks at how a new injectable drug (GZR18) affects stomach emptying and interacts with common medications like digoxin, rosuvastatin, and warfarin in 60 overweight or obese adults. Participants will receive the drug and then take these other medicines to see if there are any changes in how they work. The goal is to gather safety and dosing information, not to treat obesity directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY OR OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Study site 01
RECRUITINGBeijing, China
Conditions
Explore the condition pages connected to this study.